Research Antibodies Industry Overview

The global research antibodies market size was valued at USD 1.59 billion in 2023 and is expected to grow at compound annual growth rate (CAGR) of 4.76% from 2024 to 2030.

B cells are responsible for producing antibodies, which are essential components of the human immune system. These molecules are ideal probes for studying cells since they can attach themselves to particular molecules and can be employed to separate or identify important chemicals found in cells. These attributes of antibodies are anticipated to drive their adoption in various research applications in the near future. The outbreak of COVID-19 has created lucrative opportunities in the research antibodies market. Several leading pharmaceutical companies are investing heavily in R&D to create brand-new vaccinations, treatments, and testing tools for this pandemic.

Gather more insights about the market drivers, restrains and growth of the Research Antibodies Market

The need for research antibodies has greatly increased as a result of these intense R&D operations for the development of novel vaccination and therapy techniques. Additionally, a number of public and commercial entities are making significant efforts to fund the development of COVID-19 vaccines and therapeutics. For instance, in April 2020, Emergent BioSolutions, a biopharmaceutical company, received USD 14.5 million from the federal government to work on an antibody therapy study for COVID-19.

In addition, antibodies are currently one of the most crucial tools for research projects exploring the functions of various proteins in cells. The prevalence of neurodegenerative conditions including Huntington's disease, Multiple Sclerosis, and Parkinson's disease is fueling research prospects aimed at better understanding of such diseases. Furthermore, the increase in geriatric population and a dearth of remedies for chronic diseases have also contributed to a sharp increase in demand for research antibodies to create customized medicines, cutting-edge pharmaceuticals, and novel & effective treatments.

One of the key reasons fueling the growth of the market for research antibodies is the increase in demand for high-quality antibodies for reproducible research. The market is also witnessing growth due to the expanding landscape of proteomics and genomics research as well as increased research and development efforts in the life sciences domain. Furthermore, the market is also influenced by the rise of industry-academia partnerships as well as the expanding stem cell research and neurobiology research fields to provide for the unmet medical needs across the globe.

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global proteomics market size was estimated at USD 24.29 billion in 2023 and is projected to grow at a CAGR of 13.10% from 2024 to 2030.
• The global biomarkers market size was estimated at USD 81.04 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 13.36% from 2024 to 2030.

Research Antibodies Market Segmentation

Grand View Research has segmented the global research antibodies market on the basis of product, type, technology, source, application, end-use, and region:

Research Antibodies Product Outlook (Revenue, USD Billion, 2018 - 2030)

• Primary Antibodies
• Secondary Antibodies

Research Antibodies Type Outlook (Revenue, USD Billion, 2018 - 2030)

• Monoclonal Antibodies
• Polyclonal Antibodies

Research Antibodies Technology Outlook (Revenue, USD Billion, 2018 - 2030)

• Immunohistochemistry
• Immunofluorescence
• Western Blotting
• Flow Cytometry
• Immunoprecipitation
• ELISA
• Others

Research Antibodies Source Outlook (Revenue, USD Billion, 2018 - 2030)

• Mouse
• Rabbit
• Goat
• Others

Research Antibodies Application Outlook (Revenue, USD Billion, 2018 - 2030)

• Infectious Diseases
• Immunology
• Oncology
• Stem Cells
• Neurobiology
• Others

Research Antibodies End Use Outlook (Revenue, USD Billion, 2018 - 2030)

• Academic & Research Institutes
• Contract Research Organizations
• Pharmaceutical & Biotechnology Companies

Research Antibodies Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
  • Singapore
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Key Companies profiled:

• Abcam Plc.
• Merck KGaA
• Thermo Fisher Scientific, Inc.
• Cell Signalling Technology, Inc.
• Santa Cruz Biotechnology Inc.
• PerkinElmer, Inc.
• Becton, Dickinson and Company
• Bio-Techne Corporation
• Proteintech Group, Inc.
• Jackson ImmunoResearch Inc.

Recent Developments

• In July 2023, Bio-Techne Corporation announced the completion of acquisition of Lunaphore. The intent of this business decision was to augment the companies’ spatial biology leadership in the fields of translational and clinical research.
• In June 2023, Cell Signaling Technology (CST) announced its partnership with Lunaphore. This initiative was aimed at enabling the deployment of CST antibodies on the COMET platform by Lunaphore for strengthening fully-automated spatial biology.
• In April 2023, Abcam teamed up with Lunaphore to co-commercialize primary antibodies from Abcam. These antibodies were precisely validated for use on the COMET platform by Lunaphore.
• In February 2023, Cell Signaling Technology entered into a partnership with Bio-Techne. This deal was aimed at the inclusion of Bio-Techne’s Simple Western validation to CST antibodies.

Order a free sample PDF of the Research Antibodies Market Intelligence Study, published by Grand View Research.